Drug Discovery Strategies, PBPK Modeling and Drug-Drug Interaction Explored and Explained

This year’s 12th annual ADMET conference and exhibition promises to deliver appearances from experienced pharmaceutical professionals from ADME and PK/PD organisations such as AbbVie, GSK, Roche and Bayer when it returns to London this June.

The carefully selected speaker line up will be addressing early ADME application strategies and discussing the latest technologically advanced screening and testing models along with exploring ADMET technologies which will identify properties of a drug candidate in the preclinical stage of drug discovery, structure based prediction of ADME properties, PK/PD modelling to validate drug targets and toxicity to name a few.

Delegates can expect to hear topical discussions on Drug Discovery Strategies, PBPK Modeling and Spectrometry, Pharmacokinetics and Inhibitors on Day 1. Day 2 will see speakers exploring ADME properties and preclinical impact, strategies for accurate human dose predictions, drug-drug interactions and transfers.

For a more detailed overview of the 2 day conference, visit the event website: www.admet-event .com/openpr

Delegates will also be afforded the opportunity to truly maximise their potential by attending the post-conference interactive workshop on Wednesday 14th June 2017. This additional session has been carefully structured to provide delegates with additional hands on training whilst complementing the topics of discussion covered throughout the conference.

Drug Transporter Tool Kit
Wednesday 14th June 2017 | 08.30am - 12.30pm
Hosted by: Kunal Taskar, Associate GSK Fellow, GSK

2017 CONFERENCE HIGHLIGHTS
• Access presentations from over 20 industry specialists
• Join our exclusive interactive post conference workshop
• Updates on pre-clinical in vivo pharmacology testing and translational PK/PD
• 5+ hours of networking opportunities with senior industry professionals
• Learn about new technologies for ADMET testing, including computer based testing
• Hear the latest developments in PD/PK optimisation for drug design and discovery and DMPK from senior industry representatives
• Predictive human toxicity, transporters and ADMET studies from Vertex, Merck KGaA, GSK
• Listen to presentations explaining methods to predicting drug-drug Interactions with in vivo and in vitro data knowledge
FEATURED SPEAKERS:
• Ajit Narang, Senior Scientist, Genentech
• Andreas Reichel, VP, Head Research Pharmacokinetics, Bayer
• Carl Petersson, Associate Director Drug Disposition, Merck KGaA
• Eric Blomme, Vice President Preclinical Safety, AbbVie
• Handan He, Director, Section Head, Nonclinical PK/PD, Novartis
• Jackie Bloomer, Director, IVIVT, PTS, GSK
• Kiyoyuki Omoto, Scientist, Associate Research Fellow, Pfizer
• Kunal Taskar, Senior Investigator & Associate Fellow, GSK
• Laurent Salphati, Principal Scientist, Genentech
• Ben-Fillippo Krippendorff, Franchise Leader PK/PD Immunology & Inflammation, Roche

There is currently a £200 early bird discount for all bookings made before 31st March 2017. For more information visit www.admet-event.com/openpr

12th ADMET 2017
12th – 13th June 2017
London, UK
www.admet- event.com/openpr
Follow the conversation on Twitter and LinkedIn at #smiADMET17

About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Contact Information:
For sponsorship opportunities contact Alia Malick on +44 (0) 20 7827 6168
or email: amalick@smi-online.co.uk

For media enquiries contact Kyra Williams on +44 (0) 20 7827 6012 or email kwilliams@smi-online.co.uk

1 Westminister Bridge Street,
London,
SE1 7XW

This release was published on openPR.